Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
Cancer Treatment Reviews|July 20, 2025
De-escalation strategies with targeted therapies in non-small cell lung cancerMartina Bortolot, Jordi Remon, Paolo Bironzo, et al.
Lung Cancer (Amsterdam, Netherlands)|July 14, 2005
Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancerRafael Rosell, Yukito Ichinose, Miquel Taron, et al.
Future Oncology (London, England)|April 15, 2008
Translational research in glioblastoma multiforme: molecular criteria for patient selectionRafael Rosell, Ramon de Las Peñas, Carme Balaña, et al.
Autoimmunity Reviews|December 16, 2019
Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological patternAna Matas-García, José C Milisenda, Albert Selva-O'Callaghan, et al.
The Lancet Regional Health. Europe|March 13, 2024
Challenges and controversies in resectable non-small cell lung cancer: a clinician's perspectiveIlias Houda, Chris Dickhoff, Carin A Uyl-de Groot, et al.
Cancers|April 30, 2021
EBUS-TBNA Cytological Samples for Comprehensive Molecular Testing in Non-Small Cell Lung CancerRoberto Martin-Deleon, Cristina Teixido, Carmen Mª Lucena, et al.
Translational Lung Cancer Research|October 24, 2025
Multimodal prehabilitation to prevent loss of cardiorespiratory fitness in patients with locally advanced lung cancer undergoing chemoimmunotherapy: protocol for a non-randomized multicentre studyYu Xiao Chen, Raquel Sebio-Garcia, Maria Jose Arguis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 23, 2025
Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief ReportXiuning Le, Christina Baik, Byoung Chul Cho, et al.
Molecular Oncology|May 31, 2021
NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatmentEstela Sánchez-Herrero, Roberto Serna-Blasco, Vadym Ivanchuk, et al.
JAMA Oncology|June 4, 2021
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized TrialSalma K Jabbour, Ki Hyeong Lee, Nikolaj Frost, et al.
Pageof 8